tuneTypical Dose
1500-3500 mg per day (gelatinized maca root powder)
Botanical
Lepidium meyenii
tuneTypical Dose
1500-3500 mg per day (gelatinized maca root powder)
watchEffect Window
Sexual desire improvements typically emerge at 4-8 weeks. Some users report energy effects earlier. Mood benefits in postmenopausal women seen at 6 weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Maca may modestly improve sexual desire and some menopause- or LOH-related symptom scores without changing hormone levels, but the evidence is small and mostly subjective.
Lepidium meyenii (maca) is a cruciferous root cultivated at high altitude in the Peruvian Andes. Modern clinical trials show recurring signals for improved sexual desire and some mood or symptom-score benefits in a few settings, including postmenopausal women and eugonadal men with late-onset-hypogonadism symptom complaints. Notably, maca still does not appear to alter serum testosterone, estrogen, or other reproductive hormones. The mechanisms underlying its effects remain poorly understood, and the evidence base is limited by small sample sizes, subjective endpoints, and product-specific preparations.
Maca improves sexual desire through non-hormonal pathways that are not fully characterized. Macamides interact with the endocannabinoid system via FAAH inhibition. Does not alter serum testosterone, estrogen, LH, FSH, or prolactin. May modulate CNS reward circuitry and stress-axis responses. Adaptogenic properties reduce stress-related behavioral changes in animal models.
Article
Maca (Lepidium meyenii) is a cruciferous root vegetable native to the high plateaus of the Peruvian Andes, where it grows at elevations above 4,000 meters. It has been cultivated and consumed as a dietary staple and medicinal food for at least 2,000 years. The root is typically dried and ground into a powder, which is the form used in both traditional preparations and modern supplements.
Maca is marketed primarily for sexual enhancement, energy, fertility, and hormonal balance. Some of these claims have meaningful clinical support. Others are significantly exaggerated. The most important thing to understand about maca's evidence is that it consistently improves subjective measures of sexual desire without consistently changing objective hormonal markers. This dissociation between desire and hormones is the central puzzle of maca pharmacology.
Different color varieties of maca (yellow, red, black) have been proposed to have distinct properties. Black maca is most associated with spermatogenesis and male fertility in animal models. Red maca is associated with prostate size reduction in animals. Yellow maca is the most commonly studied in human trials. However, the clinical data supporting color-specific recommendations in humans is thin. Most human trials use gelatinized or dried maca powder without color specification.
Multiple clinical trials have measured serum testosterone, estradiol, LH, FSH, SHBG, and prolactin in men taking maca, and consistently found no significant changes compared to placebo. Gonzales et al. (2002) specifically measured these hormones in their landmark sexual desire trial and found that maca improved desire without altering any measured hormone.1
This is pharmacologically unusual. Most compounds that increase libido in clinical settings do so through hormonal pathways, either by raising testosterone, modulating estrogen, or affecting hypothalamic signaling. Maca appears to work through a different mechanism entirely.
The current leading hypotheses for maca's libido effects include direct effects on CNS pathways involved in sexual motivation (distinct from hormonal drive), modulation of endocannabinoid signaling (which influences reward and pleasure pathways), adaptogenic stress reduction that secondarily improves libido (stress is a major libido suppressor), and nutrient density effects in populations with marginal nutritional status.
None of these hypotheses has been conclusively validated. The honest answer is that we do not fully understand how maca increases sexual desire.
Maca contains several classes of potentially bioactive compounds. Macamides and macaenes are fatty acid amide compounds unique to maca. These interact with the endocannabinoid system, specifically the fatty acid amide hydrolase (FAAH) enzyme, and have shown effects on anxiety-like behavior and sexual function in animal models. Glucosinolates (including glucotropaeolin and related compounds) are present at high levels. While glucosinolates from other cruciferous vegetables are associated with cancer-protective effects, maca-specific glucosinolates may contribute to its unique biological profile. Alkaloids (including macaridine and lepidiline compounds) are present in small amounts and may have CNS activity, though specific mechanisms are poorly characterized.
Maca is classified as an adaptogen by some researchers, meaning it may help normalize physiological responses to stress. Animal studies show improved physical endurance, reduced stress-related behavioral changes, and modulated cortisol responses. In humans, energy and mood improvements have been reported in clinical trials, particularly in postmenopausal women, though the mechanisms are not well defined.
This is maca's strongest evidence domain.
Gonzales et al. (2002) conducted the foundational double-blind, placebo-controlled trial. Fifty-seven healthy men received 1,500 mg or 3,000 mg of maca daily or placebo for 12 weeks. Self-reported sexual desire increased significantly at both doses beginning at week 8, independent of changes in serum testosterone, estradiol, or other reproductive hormones. The effect size was moderate but consistent.1
Zenico et al. (2009) tested maca (2,400 mg daily) versus placebo in men with mild erectile dysfunction and found significant improvement in subjective sexual well-being and erectile function scores on the IIEF-5.
Brooks et al. (2008) conducted a pilot randomized trial of maca (3,000 mg daily) in men experiencing SSRI-induced sexual dysfunction. Maca improved libido scores and overall sexual function compared to placebo, suggesting potential utility for medication-induced sexual dysfunction. The sample size was small (n=20), but the signal was clear.2
Dording et al. (2008) reported similar preliminary findings for SSRI-induced sexual dysfunction, with maca showing improvement in the Arizona Sexual Experiences Scale.
A systematic review by Shin et al. (2010) concluded that limited evidence existed suggesting maca improved sexual dysfunction, but that the number of trials, total sample sizes, and methodological quality were insufficient for definitive conclusions. The evidence has grown somewhat since then, but the conclusion about limited quantity remains partially valid.
Gonzales et al. (2009) assessed maca's effects on mood and menopausal symptoms in early postmenopausal women. After six weeks of 3,500 mg maca daily, participants showed significant reductions in anxiety and depression scores and improvements in sexual function, compared to placebo. Again, no changes in serum hormone levels were detected.3
Stojanovska et al. (2015) conducted a systematic review of maca's effects on menopausal symptoms and concluded that the evidence, while limited, suggested maca may alleviate psychological symptoms (anxiety, depression) and sexual dysfunction in menopausal women. The review noted that evidence was insufficient for effects on hot flashes or other vasomotor symptoms.4
Brooks et al. (2008) also noted improvements in psychological symptoms alongside sexual function in their SSRI trial.
The overall pattern is that maca seems to improve subjective well-being, mood, and sexual function in menopausal women without altering hormonal profiles, consistent with the pattern seen in male studies.
Traditional use emphasizes maca for energy and stamina. Clinical evidence for athletic performance is limited. One small study found improved cycling time-trial performance after 14 days of maca supplementation, but this has not been replicated. More consistently, users report subjective improvements in energy and reduced fatigue, though placebo effects are difficult to rule out in these subjective outcomes.
Animal data (particularly with black maca) shows improved spermatogenesis and sperm parameters. Human data is limited. Gonzales et al. (2001) reported increased semen volume and sperm motility after four months of maca supplementation, but this was a small study (n=9 receiving maca) without placebo control in the initial design. Larger, better-controlled trials are needed before maca can be recommended specifically for male fertility.
Despite marketing claims about "balancing hormones," maca consistently fails to change measurable hormone levels in clinical trials. This is actually an important safety feature (it means maca is unlikely to cause hormonal side effects), but it contradicts the marketing narrative. If you are looking for something to raise testosterone or estrogen, maca is not going to do it based on available data.
Red maca reduced prostate weight in animal models, but human data is lacking. This should not be used as a basis for prostate health supplementation.
Very limited data exists. Some animal studies suggest improved learning and memory, particularly with black maca, but human cognitive trials are essentially absent.
The effective dose range across positive human trials is 1,500 to 3,500 mg of dried or gelatinized maca root powder daily. The Gonzales et al. sexual desire trial used 1,500 mg and 3,000 mg, both effective. The postmenopausal mood study used 3,500 mg.
A practical protocol:
Gelatinized maca (starch has been partially removed through heating) is preferred over raw maca powder because it is easier to digest and was used in several positive clinical trials. Raw maca contains higher glucosinolate content which may cause digestive discomfort in some users.5
Color-specific recommendations (black for fertility, red for prostate) are based primarily on animal data and should be considered preliminary.
Maca has been consumed as a food staple in the Andes for centuries, and this long history of dietary use provides some safety reassurance. Clinical trials consistently report minimal adverse effects.
The most commonly noted side effects are mild GI discomfort (bloating, gas), especially with raw (non-gelatinized) maca powder. Insomnia or restlessness has been reported occasionally, possibly related to the energizing effects. Headache is rare but reported.
Maca is a cruciferous vegetable and contains glucosinolates that can affect thyroid function when consumed in large amounts, particularly in iodine-deficient individuals. This is the same goitrogenic concern that applies to raw broccoli, cabbage, and kale. At standard supplemental doses in iodine-replete individuals, this is unlikely to be clinically significant, but people with thyroid conditions should be aware.
No changes in liver function, kidney function, or blood pressure have been reported in clinical trials. No significant drug interactions have been identified, though formal interaction studies are limited.6
Maca is generally considered compatible with hormonal medications because it does not alter hormone levels, but this has not been rigorously tested. People on hormone replacement therapy, oral contraceptives, or anti-androgen/anti-estrogen treatments should discuss maca with their prescribing physician.
Maca is one of the more honest stories in the supplement world. It does appear to do something meaningful for sexual desire, and probably for mood and subjective energy, in both men and women. The effect sizes are moderate, not dramatic, and the onset requires weeks of consistent use.
What makes maca interesting is the hormonal paradox. It improves desire without changing hormones, suggesting it works through pathways we do not fully understand yet, possibly involving CNS reward circuits, endocannabinoid modulation, or stress-axis normalization. This makes it a genuinely novel pharmacological profile, not just another testosterone booster.
The main limitations are small trial sizes, limited mechanistic understanding, and insufficient evidence for the more aggressive marketing claims (fertility enhancement, hormonal balance, athletic performance).
Maca is a food-derived supplement with a reasonable evidence base for improving sexual desire and possibly mood, a favorable safety profile, and no hormonal side effects. It is not a miracle aphrodisiac. It is a modest, slow-acting botanical that may help people who experience reduced desire or mood-related quality of life issues, particularly postmenopausal women and men with medication-induced sexual dysfunction.
What maca is good for:
What maca is not established for:
If you use maca, commit to at least 8 weeks at 1,500 to 3,000 mg daily, use gelatinized form for digestibility, and evaluate based on subjective experience rather than blood work, because it will not change your hormone levels.7
Gonzales et al. (2002) showed maca improved sexual desire at 8 weeks in healthy men at both 1500 mg and 3000 mg daily, without altering serum testosterone, estradiol, LH, FSH, or prolactin.
↩Brooks et al. (2008) found maca (3000 mg daily) improved libido and sexual function in men with SSRI-induced sexual dysfunction in a small pilot RCT (n=20).
↩Gonzales et al. (2009) demonstrated significant reductions in anxiety and depression scores and improved sexual function in early postmenopausal women after 6 weeks of maca (3500 mg daily) versus placebo, without hormonal changes.
↩Stojanovska et al. (2015) systematic review concluded maca may alleviate psychological symptoms and sexual dysfunction in menopausal women, with insufficient evidence for vasomotor symptoms.
↩Gelatinized maca is preferred for supplementation because partial starch removal through heating improves digestibility and was used in several positive clinical trials.
↩No significant changes in liver function, kidney function, blood pressure, or hormone levels have been detected in clinical trials of maca at standard supplemental doses.
↩Maca's central pharmacological puzzle is improving subjective sexual desire and mood through non-hormonal pathways, possibly involving endocannabinoid modulation or CNS reward circuit effects.
↩Outcomes
Safety
Evidence
Gonzales GF, Córdova A, Vega K, Chung A, Villena A, Góñez C, Castillo S. Effect of Lepidium meyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Andrologia. 2002;34(6):367-372. doi:10.1046/j.1439-0272.2002.00519.x. PMID:12472620.
Population: Healthy adult men.
Dose protocol: 1500 mg or 3000 mg maca daily for 12 weeks
Key findings: Sexual desire increased significantly at both doses beginning at week 8 compared to placebo. No changes in serum testosterone, estradiol, LH, FSH, SHBG, or prolactin.
This foundational maca RCT randomized 57 healthy men to placebo, 1.5 g/day maca, or 3 g/day maca for 12 weeks. Sexual desire improved in the maca groups from week 8 onward, while testosterone and estradiol remained unchanged. The study remains important because it established the central clinical pattern that still defines maca today: subjective libido benefits without hormone elevation. That makes the effect interesting, but it also means the study supports symptomatic sexual-desire framing rather than testosterone-booster marketing.
Dording CM, Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neurosci Ther. 2008;14(3):182-191. doi:10.1111/j.1755-5949.2008.00052.x. PMID:18801111.
Population: Remitted depressed outpatients with SSRI-induced sexual dysfunction.
Dose protocol: 3000 mg maca daily for 12 weeks in men with SSRI-induced sexual dysfunction
Key findings: Maca improved libido and overall sexual function scores compared to placebo in a small pilot RCT. Suggests potential utility for medication-induced sexual dysfunction.
This small pilot RCT tested maca as a possible treatment for SSRI-induced sexual dysfunction. Only the 3.0 g/day group showed significant improvement on ASEX and MGH-SFQ sexual-function scores, and libido improved in pooled analyses. The study is useful because it adds a distinct medication-induced sexual-dysfunction use case to the maca literature, but the sample was tiny, there was no placebo arm, and the trial was designed more as dose finding than as definitive efficacy confirmation. It supports a narrow, low-confidence niche rather than broad sexual-function claims.
Brooks NA, Wilcox G, Walker KZ, Ashton JF, Cox MB, Stojanovska L. Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause. 2008;15(6):1157-1162. doi:10.1097/gme.0b013e3181732953. PMID:18784609.
Population: Postmenopausal women with climacteric symptoms.
Dose protocol: 3500 mg maca daily for 6 weeks in early postmenopausal women
Key findings: Significant reductions in anxiety and depression scores and improved sexual function versus placebo. No changes in serum hormone levels detected.
This placebo-controlled crossover trial is one of the main reasons maca is discussed for menopausal mood and sexual-function complaints. Fourteen postmenopausal women took 3.5 g/day maca and placebo in alternating 6-week periods. Maca improved psychological symptoms, including anxiety and depression, and improved sexual-dysfunction measures without changing estradiol, FSH, LH, or SHBG. The trial supports a real non-hormonal symptom signal, but the sample was very small and should not be overread as proof of broad menopause efficacy.
Stojanovska L et al. Maca reduces blood pressure and depression, in a pilot study in postmenopausal women. Climacteric. 2015;18(1):69-78.
Population: 29 postmenopausal women
Dose protocol: Systematic review of maca for menopausal symptoms
Key findings: Concluded maca may alleviate psychological symptoms and sexual dysfunction in menopausal women. Evidence insufficient for vasomotor symptoms. Noted need for larger, higher-quality trials.
This pilot RCT examined the effects of maca supplementation at 3.3g/day for 6 weeks in postmenopausal women. Maca significantly reduced depression scores and lowered diastolic blood pressure compared to placebo. These findings add to the evidence that maca has meaningful effects on mood in postmenopausal populations and suggest a possible cardiovascular benefit through blood pressure reduction. The dual effects on mood and blood pressure may share underlying mechanisms related to stress physiology and vascular function.
Lee HW, Lee MS, Qu F, Lee JW, Kim E. Maca (Lepidium meyenii Walp.) on semen quality parameters: A systematic review and meta-analysis. Front Pharmacol. 2022;13:934740. doi:10.3389/fphar.2022.934740. PMID:36110519.
Population: Men with infertility and healthy men across five RCTs.
Dose protocol: Maca supplementation across five RCTs measuring semen quality parameters
Key findings: No significant efficacy for sperm concentration versus placebo. Overall effects on semen quality parameters were unclear. Total number of RCTs and sample size too small for firm conclusions.
Notes: Formally quantifies the weakness of male fertility evidence for maca.
This systematic review and meta-analysis examined five RCTs of maca supplementation on semen quality parameters. The pooled analysis showed no significant efficacy for sperm concentration versus placebo, and overall effects on semen quality parameters were unclear. The authors concluded that the total number of RCTs and total sample size were too small to draw firm conclusions. This study is useful because it formally quantifies the weakness of the male fertility evidence for maca, confirming that fertility claims remain insufficiently supported by controlled human data.
Shin D, Jeon SH, Piao J, Park HJ, Tian WJ, Moon DG, Ahn ST, Jeon KH, Zhu GQ, Park I, Park HJ, Bae WJ, Cho HJ, Hong SH, Kim SW. Efficacy and Safety of Maca (Lepidium meyenii) in Patients with Symptoms of Late-Onset Hypogonadism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. World J Mens Health. 2023;41(3):692-700. doi:10.5534/wjmh.220112. PMID:36593713.
Population: Eugonadal adult men with symptoms of late-onset hypogonadism.
Dose protocol: 6 g/day gelatinized maca for 12 weeks in eugonadal men with LOH symptoms
Key findings: AMS, IIEF, IPSS, and ADAM symptom measures improved versus placebo, without establishing a testosterone-mediated effect.
Notes: Useful modern symptomatic-support trial, but still not proof of hormone restoration.
This 12-week double-blind RCT tested high-dose gelatinized maca in 80 eugonadal men with late-onset-hypogonadism symptom complaints rather than biochemical hypogonadism. Compared with placebo, maca improved Aging Males' Symptoms scores, erectile-function scores, lower-urinary-tract symptom scores, and ADAM screening status. The trial is useful because it reinforces the broader maca pattern of improving subjective sexual and well-being outcomes without establishing a testosterone-mediated effect. It does not show hormone restoration, fertility benefit, or disease modification, and the symptom-based endpoints plus company involvement keep the findings moderate rather than definitive.